LAUSR

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms of the gastrointestinal tract albeit an annual incidence of 11 per million people, and it accounts for 1% of primary gastrointestinal malignancies. GISTs are thought to originate from the interstitial cell of cajal, which is a pace-maker cell that regulates the gastrointestinal tract motility [1]. GISTs may arise anywhere in the alimentary tract; stomach (50–60%), small bowel (30–35%), colorectum (5%), and esophagus (<1%). GISTs arising as primary tumors outside the gastrointestinal tract compromise <5% of all GISTs and are called extra-gastrointestinal stromal tumor (EGIST) [2]. The most common site of EGIST is omentum. Mesenteric and retroperitoneal EGIST is very rarely reported [2, 3]. Small-bowel mesentery (SBM) root, that is contiguous with the pararenal spaces, extends diagonally from its origin at the Treitz ligament inferiorly and toward the ileocecal valve. The root of SBM is surgically a strategic location due to major vessels; superior mesenteric artery (SMA) and superior mesenteric vein (SMV) [4]. Therefore, surgical treatment of EGIST in mesenteric root may be different from other EGIST/GIST. Besides, prognosis and outcome of the disease may also be different. To our knowledge, 14 primary mesenteric EGIST has been reported in English literature until now [5]. Aim of the study is to report a huge mesenteric root EGIST that is located in a critical anatomical region and discuss treatment options and oncological outcomes.